(Q33493614)

27 July 2017

title

Intraprostatic Botulinum Toxin Type A injection in patients with benign prostatic enlargement: duration of the effect of a single treatment (English)

1 reference

27 July 2017

main subject

botulinum toxin type A

1 reference

João Silva

1

0 references

Francisco Botelho

Francisco Botelho

4

0 references

Rui Pinto

Rui Pinto

2

0 references

Carlos Silva

Carlos Silva

7

0 references

Francisco Cruz

Francisco Cruz

8

0 references

author name string

Tiago Carvalho

3

1 reference

27 July 2017

Pedro Silva

5

1 reference

27 July 2017

Rui Oliveira

6

1 reference

27 July 2017

Paulo Dinis

9

1 reference

27 July 2017

publication date

15 August 2009

1 reference

27 July 2017

1 reference

27 July 2017

volume

9

1 reference

27 July 2017

page(s)

9

1 reference

Development of future indications for BOTOX.

27 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734751

Relief by botulinum toxin of lower urinary tract symptoms owing to benign prostatic hyperplasia: early and long-term results

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734751

Does prostate growth confound prostate specific antigen velocity? Data from the Baltimore longitudinal study of aging

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734751

Is botulinum neurotoxin type A (BoNT-A) a novel therapy for lower urinary tract symptoms due to benign prostatic enlargement? A review of the literature

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734751

Cholinergic innervation and muscarinic receptors in the human prostate

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734751

Intraprostatic botulinum toxin type a injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement. Effect on prostate volume and micturition resumption

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734751

Resiniferatoxin and botulinum toxin type A for treatment of lower urinary tract symptoms.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734751

Evaluation of short term clinical effects and presumptive mechanism of botulinum toxin type A as a treatment modality of benign prostatic hyperplasia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734751

Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734751

Intraprostatic injection of botulinum toxin type-A relieves bladder outlet obstruction in human and induces prostate apoptosis in dogs

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734751

Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734751

Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734751

5alpha-reductase inhibitors: what role should they play?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734751

Evaluation of symptoms and quality of life in men with benign prostatic hyperplasia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734751

Botox-induced prostatic involution

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734751

Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy

21 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-2490-9-9

Mechanisms of prostate atrophy after glandular botulinum neurotoxin type a injection: an experimental study in the rat.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-2490-9-9

Effects of botulinum toxin A on the contractile function of dog prostate.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-2490-9-9

Prostate botulinum A toxin injection--an alternative treatment for benign prostatic obstruction in poor surgical candidates

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19682392

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19682392

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1471-2490-9-9

1 reference

Dimensions Publication ID

27 July 2017

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-2490-9-9

9 September 2019

1 reference

27 July 2017

1 reference